BCR and leukemia: Our findings showed that STAT5, more particularly, STAT5a, plays a critical role in TA regulation, suggesting that inhibition of STAT5a in combination with BCR-ABL may provide an alternative approach for treatment of leukaemia, especially in patients who are resistant to tyrosine inhibitors.